Good day and thank you for standing by for the 2021 fourth quarter Dentsply Sirona earnings conference call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question and answer session. To ask a question during that session, you will need to press star, one on your telephone. Please be advised that today’s conference is being recorded, and if you require any assistance during the call, please press star, zero. I would now like to hand the conference over to your speaker today, Ms. Andrea Daley, Vice President of Investor Relations. Ms. Daley, the floor is yours.

Thank you Chris and good morning everyone. Welcome to our fourth quarter and full year 2021 earnings call. Joining me for today’s call is Don Casey, our Chief Executive Officer, and Jorge Gomez, our Chief Financial Officer. I would like to remind you that an earnings call press release and slide presentation related to the call are available in the Investors section of our website at www.dentsplysirona.com. Before we begin, please take a moment to read the forward-looking statements in our earnings press release. During today’s call, we’ll make certain predictive statements that reflect our current views about future performance and financial results. We base these statements and certain assumptions and expectations on future events that are subject to risks and uncertainties. Our Form 10-K lists some of the most important risk factors that could cause actual results to differ from our predictions. In today’s conference call, our remarks will be based on non-GAAP financial results. We believe that non-GAAP financial measures provide investors with useful supplemental information about financial performance of our business, enables the comparison of financial results between periods or certain items may vary independently of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business. Please refer to our press release for the reconciliation between GAAP and non-GAAP results. With that, I’d like to turn the call over to Don Casey.

Thank you Andrea, and thank all of you for joining us this morning for the Dentsply Sirona fourth quarter and full year 2021 earnings call. There’s a lot to cover today. Before getting into the discussion, I wanted to thank our team at Dentsply Sirona. Looking at the challenges through the last two years, there have been a few constants. The first is that dentists have shown tremendous perseverance and creativity throughout the pandemic, underscoring the resilience of the dental industry. The other is our team at Dentsply Sirona. Every day, they continue to demonstrate unwavering commitment to our customers and our mission of transforming dentistry. Across the entire company, our thoughts are also with the people and our colleagues in Ukraine. We have a great team there and we will continue to support them however possible. Moving on today, we will cover four items, starting with an overview of 2021, then Jorge will cover our Q4 financials and provide a 2022 outlook. I will finish by providing a strategic operating update. We are proud of our performance in 2021. Dentsply Sirona delivered robust organic sales and EPS growth as well as solid cash generation. There was also significant progress against our critical strategic initiatives. An excellent example of that progress were the two announcements we made last week. Those included a strategic collaboration with Google Cloud and the launch of a 3D printer later this year. Both of these represent important milestones and highlight our commitment to transforming digital dentistry. Moving now to Slide 6, as I mentioned, our financial performance for 2021 was strong with revenues reaching $4.25 billion. This represents a robust 24.6% increase on an organic basis versus 2020 that was also represent an organic growth rate of 4.9% versus 2019. Our operating margin was 20.5% with SG&A and R&D investments increasing over the year with the pace of the recovery. Adjusted EPS was $2.87 and on a full year basis we generated strong operating cash flow of $657 million. To provide more details on our financial performance, I will now turn the call over to Jorge.

Thank you Don. Good morning, and thanks to all of you for joining us. Today I will cover fourth quarter results, fiscal year ’21 performance, our current outlook for ’22, and an update on our capital allocation policy. As a reminder, my remarks today will be based on non-GAAP financial results unless otherwise noted. Please refer to the reconciliation tables at the back of the press release and slides, both of which are posted in the Investors section of our website. In the fourth quarter, we delivered revenue of $1.088 billion with organic sales growth of 1.8% and reported growth of 0.6%. Our clear aligners, implants, and CAD/CAM businesses posted a strong growth in the quarter. In line with our expectations, consumables declined versus last year. In the quarter, we also experienced more acute supply chain and COVID-related constraints which we estimate to have suppressed our total company organic growth by approximately two to three points. We view this as a temporary headwind but anticipate that our supply chain will remain challenged for at least one or two quarters in 2022. Gross profit was $627 million or 57.7% of sales. Our margin rate increased 100 basis points year-over-year driven by benefits from portfolio optimization and efficiency improvements offset by inflationary cost pressures. SG&A expenses were $351 million or 32.3% of sales. SG&A as a percent of sales increased 290 basis points year-over-year primarily due to commercial investments in growth areas, including clear aligners, implants, and digital capabilities. Additionally, SG&A ran at a lower rate in the prior year quarter as we were still ramping back up to our normal pace of operations. R&D spend was $59 million, an increase of 32.2% year-over-year. This increase reflects our focus on innovation and a $10 million one-time re-class of R&D expenses reflected as…

Thank you Jorge. Moving on, I wanted to provide some perspective on our strategy and priorities going forward. In late 2018, we had outlined a program to accelerate growth, improve margin, and to simplify the organization. Despite challenges, we have largely achieved the targets that we had laid out. Just as important, our team has also sharpened our strategy while improving our innovation capabilities. As Jorge said, going forward we expect to build on those capabilities to deliver reliable 4% to 5% growth in revenue, continuous improvement in our margins, and double-digit earnings growth. We believe our strategy of delivering superior integrated workflows in critical procedures will allow Dentsply Sirona to become the indispensable digital partner to the dentist. On Slide 23, we outline that strategy. It calls for us to build on our large installed digital base, whether it’s Primescan, Orthophos, or Axeos. All of these offer dentists among the best-in-class diagnostic capabilities that are so essential as dentists globally look to enhance their ability to do more dentistry. These diagnostic capabilities feed into our outstanding treatment offerings in four of the essential dental work flows. Those areas include implants, clear aligners, restorations and endodontics. All this helps make Dentsply Sirona a real leader in shaping the future. I would like now to outline progress in each of these areas, starting with digital dentistry. There was strong progress within the CEREC franchise during 2021. In addition to a record number of DI cameras sold, we were able to launch major software innovations with CEREC 5.2 and Sure Smile 7.6. There was also good progress on Primemill. Our higher end CBCT imaging systems also saw robust demand that stems from dentists looking to add more sophisticated diagnostic tools that will allow them to incorporate more complex procedures like implants and…

[Operator instructions] Our first question comes from Elizabeth Anderson of Evercore. Your line is open.

Hi guys, thanks so much for the question this morning. I guess my first question, I just want to make sure I fully understand the omicron impact on fourth quarter results, and then I think you commented qualitatively the impact to January results, but as we sit here on the last day of February, it would be helpful if you could just provide any more color around the progression across December, January and February.

Good morning Elizabeth. The last week or two in December became more complicated for dental practices in many markets, primarily as a result of staffing shortages and as a result volume tended to go down a little bit, again in the last couple of weeks in December in a lot of markets. We had also situations like China, where many provinces still have the zero COVID policy and as a result were in major lockdowns, which restricted substantially patient traffic, so those are probably the two main constraints we were facing from a volume, from a demand perspective. Some of that went over into January, and as we look at volumes in the month of January, we observed a slower than normal volume, and that’s based on what you can see with respect to COVID infection curves. Clearly in the U.S., the situation has improved. I would say Europe is probably a couple weeks behind, meaning they picked up later than we did in the U.S. The situation in Asia-Pac, particularly China is still fluid because a lot of cities remain in lockdown. I think there is an expectation that over the next few weeks, things will become more normalized, but as you all know, the volatility has been high with respect to those type of reactions to spread, the spread of omicron.

Got it, that’s helpful, thank you. Then you obviously talked about the launch of the new Primeprint product. I was wondering if you could talk about the commercial launch calendar for those various regions and how you expect sales to contribute to 2022 results there.

Yes Elizabeth, let me start and I’ll let Jorge comment specifically on the sales cadence. Our expectation is toward the end of the second quarter, we’ll roll Print - it’ll be a global launch, but principally focused on our DOC and North American regions. Right now, we’re very, very excited, and I’d urge everyone to hit our virtual event on Friday - with things like Chicago midwinter, you kind of have to create virtual events. We’re really excited about Primeprint. We’ve had it in alpha and beta testing now for close to a year, and the reaction from the dentists is really positive. The cadence will literally go North America and mostly Central Europe first. It will be global pretty much by the third quarter. There’s a couple components to it, Elizabeth, that I’d draw your attention to in the prepared remarks. Obviously there’s a lot of follow-on stuff like the printing ink, and we’re also committed to offering a service package which will let a dentist actually outsource the treatment planning and the design work for using the printer, which we’re pretty excited about as well. Jorge, you may want to comment on the specific revenue--

Yes Don, I think you explained the cadence from a geographical standpoint. Just to re-emphasize, U.S. first and a few selected markets in Europe. We plan to do that sometime in the third quarter. There are a few things that we still need to finish and to firm up, including I mentioned in my prepared remarks there are supply chain constraints with electronic components, that is a consideration for us, and then we have to fine tune pricing and the overall economics of the printer. We have incorporated in our financials for ’22 some contribution from Primeprint. We have it ranged, and it is included in our guidance. We will fine tune those estimates as we get closer to the summer, as we get closer to the actual launch date for the product.

Okay, thanks so much, guys.

You’re welcome.

Thank you. Our next question comes from the line of Nathan Rich of Goldman Sachs. Your line is open.

Hi, good morning. Thanks for the questions. I maybe wanted to start with the supply chain disruption that you mentioned and the impact on imaging and some of the other categories within the equipment portfolio. I guess Don and Jorge, I’d be curious just to get your sense of how much visibility you have on the--your ability to kind of get the components that you need and how you’re assuming that plays out over the course of the year, and also what impact that might have on the cost of production, and have you seen any indications that those supply constraints have started to ease in the first couple months of this year?

Good morning Nathan, let me take that. The amount of visibility into electronic components shortages is complicated not only for us, but in all industries. We have compared notes with multiple other companies that actually use the same type of electronic components and the supply of those products is very inconsistent. Some people believe that the issues will ease sometime in the first half of the year, other people believe that the situation could last longer, so it’s really hard to predict not only for us but for many industries. One thing that we had been experiencing before this quarter, and I mentioned this a couple times, we were able to have access to all the components we needed, albeit at a higher price, so the impact had been only from a cost perspective. That cost impact is reflected in our gross margin and is impacting our gross margin, and will continue to impact our gross margin for some time. Our team is doing a terrific job trying to procure these components from multiple sources and they will continue to do so. In the fourth quarter, we had issues with, as I said before, especially 3D imaging and treatment centers, and the impact was roughly between $12 million, $14 million, $15 million across all products, and as we go into 2022 and the guidance that we have provided, we are contemplating those challenges to continue for some time, so it is to a large extent is captured there. The only one caveat is we have seen situations where certain components totally dry up in the supply chain for periods of a few days or a few weeks, so managing inventory levels, inventory levels in the network and ensuring that the production lines are balanced is a challenge for the team, and will continue to be a challenge for some time. But as I said, a lot of that risk is already captured in our numbers, in our projections.

Okay, great. That’s helpful. Maybe just to clarify, so the $12 million to $15 million of impact, that might be the rough ballpark to use for the first couple quarters of the year, and then hopefully the supply eases beyond that. Jorge, just if I could kind of tie in my follow-up to that, how are you thinking about the cadence of margins over the balance of the year? I understand you’re kind of working to get to 22% by the fourth quarter. Can you maybe talk about how that plays out over the balance of the year, and also if you have any updated thoughts on beyond 2022, what we should expect in terms of annual margin expansion from the business. Thank you.

Yes Nate, one thing on the $12 million to $15 million in Q4, I would ask you not to extrapolate because those numbers fluctuate all the time, so that was the impact specifically in Q4. The impact in Q1 could be similar, it could be less, could be more, so it is always a range, so I would not extrapolate. Our projections show, or our expectation from supply chain is that we should be able to recover in the next couple of quarters, but that situation could change, so that’s a fluid situation. Your second question about cadence of margins, I indicated in my prepared remarks we expect the first half to be lower, and a number of factors come into consideration here. One, as you know, Q1 is always a low quarter from a volume perspective, and that results in lower margins. We also have the mathematical effect of Bite, so Bite we expect to decline in the first half versus last year, and so that is a headwind. Then we have some of the supply chain issues that I talked about, so that’s going to depress margins in the first half. As we go into the second half, then there are tailwinds; for example, Bite we expect to be a contributor to growth in the second half. We expect the acceleration of product launches to gain traction. We are pretty excited about the progression we are seeing with Pro Taper Ultimate, Primetaper and CEREC Tessera. Those products are gaining traction - they began in Q4 and they progressed throughout the year. Those are going to be important contributors to growth in the second half. Primeprint, although not very significant, is also another improvement in the second half. The last point I would indicate is pricing. In Q4--actually October 1 of 2021, as you know, we implemented a price increase that is going to start annualizing now, so that helps ’22 first three quarters, and then we have the opportunity and we will monitor the market and we’ll potentially do more price increases throughout 2022. The inflationary environment is real, it’s happening. Costs are going up and pricing is also something that we can use to offset some of those incremental costs, and hopefully have a net positive impact from pricing. Hopefully that helps with respect to the cadence for ’22. Beyond ’22, good question. We’ve talked about this before. I think we always--once we are at the level of 22% operating profit margin rate, for us it’s going to be really important to balance growth, top line growth with further margin expansion. I think a 22% margin rate is reasonable. Can we do more? I think we can do more, but at that point our biggest priority, our higher priority is going to be making sure that the top line starts growing faster than we have seen so far.

Great, thanks so much for all the comments, appreciate it.

All right, you’re welcome. Next question, please?

Thank you. Next we have Michael Cherny from Bank of America. Your line is open.

Hi, good morning, and thanks for all the detail so far. I want to get a little bit to the cadence dynamic over the course of the year, and particularly into the second half. As you think about Bite in particular, think about the supply chain shortages, as you target second half growth of mid single digit organic or better, what are the areas that are potentially the most concern that won’t let you get there, and at that or better side, what’s going better to get you to that or better part?

Yes, I think the thing that concerns me most are things that are beyond our control, so what happens with supply chain throughout the year is an important consideration, and I think we are trying to be conservative and factor in the situation the best we can see it today, so that’s a challenge. In terms of things that can actually provide upside, I think new products is a possibility for upside. I think the traction, the potential acceleration of the traction we have in important businesses like clear aligners and implants is another source of upside, but I think overall what we are providing in our guidance reflects a balanced view of both downside and upside, so we think--and that’s why we’re sharing those numbers, we think those are the likely outcomes and we are confident about that range at this point.

Thanks Jorge. Then I guess one other question on the mix in the portfolio. You did mention that portfolio evolution is likely expected to continue, obviously you’ve made a lot of changes the last couple years. How do you think about identifying specific areas that might make sense within the portfolio, not in the portfolio, and as we go forward, especially given some moving pieces you’ve had, should we be thinking about anything of scale that potentially doesn’t make sense within the go-forward Dentsply?

Yes, thanks for the question, Michael. Over the last three years, if you think about it, we got out of analog lab and we got out of traditional ortho, and there’s been some dribs and drabs there. We’ve also added exposure to clear aligners, which we’re excited about. At this point, we don’t see any massive needs or any--you know, tomorrow morning we’re going to get out preventative, so we continue to look at stuff, and our criteria is it growth accretive, is it margin accretive, is there a place that we can add real value through R&D, and is it essential to our digital work flows. If it meets those criteria, we’ll keep and invest in them; if it doesn’t, we’ll look to harvest them, whether harvested means look to maximize profit on those businesses or potentially divest them, we’ll make those decisions, but I think the scale of the activity you’ve seen is kind of what we’d look at going forward.

Got it, thanks Don.

No problem Michael.

Next we have Kevin Caliendo of UBS. Your line is open.

Great, thanks for taking my call. First one is just on Ukraine and Russia, and obviously knowing how sensitive it is, but what you have sort of contemplated for it, where are you in terms of trying to understand the impact to your business at this point or what it might be, and how did you contemplate it? I know it’s low single digit part of your total revenues, but it’s still meaningful enough to impact things.

Good morning Kevin. It is small but meaningful, as you said. At this point in our guidance for 2022, we are not contemplating any major disruptions with respect to our commercial cadence in those geographies. The reason for that is it’s still early on and it is not very clear what is going to happen with the actual markets in the local geographies. We have no indication yet that, for example, patient traffic has slowed down as a result of this conflict, particularly in Russia. For Ukraine, it’s a lot smaller for us. From a regulatory standpoint, potential sanctions and capital flows, we don’t know yet. We’re trying to assess that. We will all learn more in the next few weeks, but at this point we have decided not to capture any downside because it is really hard to quantify at this time.

Got it, okay. That’s helpful. Just maybe a broader question, strategy question. A lot of your long term targets and guidance that you’ve provided culminated in 2022. Is there a plan at some point this year to update long term margin targets and/or cost savings programs, or even the revenue guidance which I think has been in place for a bit?

Yes Kevin, the intent right now is to--you know, we wanted to get through Q4 and talk about the year, and then get through our initial discussion about 2022, but we owe you guys an investor day, which we’re planning on doing, and at that point we’ll update where we see long term revenue and how we’re thinking about margin, how we’re thinking about earnings per share, as well as our capital allocation strategy. I would tell you one of the interesting things from my perspective is we outlined a four-year plan, we’ve been operating against the four-year plan, and there’s obviously ups and downs, pandemics and all that kind of fun stuff, but we’re pretty happy that we’re on path to complete what we said we’re going to complete on a timely basis, and we’re optimistic that when we do an investor day, probably in the middle of the year, we’re looking forward to identifying what we think our future targets are.

Great, thank you so much.

Thank you. Our next question comes from Jeff Johnson of Baird. Your line is open.

Thank you, good morning guys. Don, maybe I’ll start with a two-parter on the clear aligner business. One, you’re talking about sequential growth for Bite throughout the year and year-over-year growth in the back half of the year. It looks like to us Bite revenue may be down a couple million in fourth quarter versus third quarter, so what are you seeing that gives you confidence we might be at that bottom and be able to grow off that? Number two, your Sure Smile business, you said hit that $100 million dollar run rate. Looked like to us, at least by our numbers, that you were over $100 million for the full year as well, so not just a run rate number in Sure Smile. How are you thinking about the growth outlook for that business in ’22? It seems like that 60% growth number is maybe not sustainable, obviously, but very solid outlook in ’22. Thanks.

Yes Jeff, on Sure Smile, you got it exactly right, and then on Bite, it did in fact decline in Q4. Our sense is, and literally we get stuff that we look at on a daily and weekly, monthly basis, we’re seeing improvements. There are a couple things going on there. Obviously within the DTC category, there were changes on the competitive landscape around some of the other brands, and we’ve been sticking to our knitting, focused on how do we build more capabilities around things like search engine optimization, affiliated marketing, insurance things that we think put Bite on a much more stable growth platform, and then we’re anxious to implement what we refer to as Bite Pro, which is--again, we think we’ve got this large, underserved population that’s really not accessing dentists today, and how do we use Bite as a potential traffic generator that go into the dental office and, whether they--exactly how we look forward to using Primescan and Sure Smile is stuff that we’ll talk about in the middle of the year.

All right, that’s helpful, thanks. Jorge, I just want to understand on the operating margin, you made a comment about 22% and then you’ll see from there where it goes. Were you saying you still expect, or you would expect to get to that 22% operating margin in ’23, or were you just saying as you get there, then it will be a top line versus tradeoff to margin expansion discussion from there?

Yes Jeff, we expect to exit 2022 at the 22% top margin rate. Listen - structurally when we look at the progression over the last several years, despite some quarterly fluctuations, we are operating substantially above the margin rates the company had in the past, so in ’21 for example, we indicated at the beginning of the year that we would be over 20% throughout the year and we did that. As we go into ’22, we should be above the 21% level structurally and exit at 22%, so through all the changes we are making to our infrastructure, the changes in the mix, new products, we think in ’23 we should be operating structurally at a 22% operating profit level. Then beyond that, that was my comment--my comment was, what happens then? At that point, the trade-off between investment for higher top line growth versus continuing to expand margins will be a topic of continued debate internally to make sure that we move levers in the most effective way to create shareholder value.

Understood, thank you.

Thank you. Next we have John Kreger of Blair. Your line is open.

Hey, thanks guys, appreciate it. Wanted to follow up on the supply chain issue. Jorge, you’ve mentioned a couple of brands that it sounds like are gaining the most impact. Can you just review that again as you think about the ’22 guide, what are the product categories that you think will be most constrained by the supply chain shortages?

Yes John, thank you for the question. It is primarily imaging equipment, so one of our best selling products today is Orthophos, Axeos has been doing really well in the market. Those products are impacted by the shortages of electronic components. In addition to that, treatment centers, which are not that relevant in the U.S. but there’s a big market for treatment centers in Europe and Asia-Pac, and we are having challenges with that. Those are the two main lines, and then there is a number of random components that impact some other categories, but those are the two main ones, electronic components, kind of around the high voltage type of electronic components.

Great, thanks, and then my follow-up, kind of same topic, what drives the confidence that hopefully this situation is better in the second half? Is that just feedback you’re getting from suppliers, or are you pursuing perhaps other changes in sourcing? Thanks.

Yes, it’s all of the above. We actually in ’21, as we started to face challenges, the procurement team went out and sourced products from places that we had not bought components from in the past. That activity will continue. We are obviously having tons of conversations with our suppliers, we’re talking to many other companies, and some people believe that the situation will begin to ease sometime towards the end of the first half. In some areas, I have--I’ve heard directly from other companies where they actually have experienced in certain components already some sort of improvement, but it’s really fluid. Overall, we are not banking on a substantial improvement in the second half. What we’re modeling is a slight improvement, but we are not banking on a complete solution of the supply challenges related to imaging products.

Great, thank you.

Thank you. Next we have Jon Block of Stifel. Your line is open.

Thanks guys. Good morning. Maybe just a couple follow-ups on some topics already discussed. Just to go back to Bite for a moment, guys, I believe you said growth for full year ’22, I think that was specific to Bite, maybe what level of growth, modest growth, any color commentary there, and maybe more importantly, Don, how do you see the long term outlook for the DTC market? You’ve had this asset for 12 months. What about also the level of accretion - I think at the time you guys acquired the asset, you talked about ramping accretion into the out years. Maybe if you could just provide some color there, and then I’ll just ask a quicker follow-up.

Yes, so Jon, specifically we do expect Bite to post growth ’22 versus ’21. It’s driven off the back half. If you look at the revenue cycle of Bite, the first two quarters when we were kind of in the pandemic, pre-iOS change, there were bigger quarters, but we expect Bite to grow, that’s part one. Part two is what do we expect for the DTC market, I can’t answer completely for other competitors in the market. We’ve always looked at it as an opportunity to reach this underserved population, and our strategy was to sit there and say, look, the total clear aligner business is absolutely critical to us from a digital dentistry perspective, because dentists are making choices about scanners and other things based on their ability to access things like clear aligners or implants or other things, so we felt that being in the clear aligner business is offensive as well as defensive. We thought Bite was going to--and we have seen it, Bite’s going to get its critical mass in terms of manufacturing, R&D, stuff like treatment planning and whatnot. The other thing that we really felt that we needed to do was have the ability to create traffic for the dentists, and again we’re tapping into a population that just does not access dental care at the same rate as a traditional population, so the challenge for us and one that we’re optimistic, hence why we talk about Bite growing, is that we can in fact begin to build Bite’s reputation and capabilities so that it does in fact increase patient traffic at the dentist, and obviously those would be dentists that we believe are going to offer a Primescan and Sure Smile type solution. Then in the out years around accretion, look, we believe our total clear aligner business, it will be accretive from a growth perspective. We’re not going to talk specifically about the individual brands, but we like where we are in clear aligners, we like the profit profile of that business, we’ think we’re scaled today in a place that will give us an opportunity to be very, very competitive over the long term, and it’s important as we build a digital dentistry ecosystem that having access to important procedures, where we believe our treatment planning stuff like Sure Smile, like Simplant and other things really is going to mesh well with what we believe we’re creating.

Got it. That was very helpful, thanks, and also a lot of great color on the call and a great slide deck as well, so shout out to Andrea and the team. Maybe just a quick second question, supply chain challenges, look, I know it’s difficult to figure out how long it lasts, but maybe just from our end most importantly, are you worried there’s sort of breaking point where, if you’re not able to fill that backlog that’s building, you start to see any leakage? Is that possible? Is that a late 1H, an early 2H? I’m just curious, like your conviction that’s it’s more, hey, it’s in the backlog and it’s just when we’re able to service it, versus if this drags on, people might seek an alternative solution? Thanks for your time.

Yes, thanks Jon, and Andrea totally is beaming over here, so we’re going to have just try and keep her down for the rest of the day. Look, back orders are rolling back orders. It’s not as if there is no availability, full stop. What Jorge and we’ve been trying to describe is sometimes there are components, sometimes there’s not, and they’re complex. You might wind up getting the chips you need but the high voltage capacitors aren’t there. I would just tell you what we’re modeling is that there is movement on the backlog of orders. It’s not happening as fast as we would like. If we have a backlog of X-number of weeks, it doesn’t mean that there’s not any imaging. But obviously, look, if somebody places an order for something and we’re going to deliver it 18 months later, that’s a problem. What we have been doing is we go out and if we have an order from Dr. Gomez, you know, we’re out maintaining that relationship and--you know, look, a lot of our imaging business is replacement of our old imaging business. We tend to have a very loyal customer base. They’ve gotten very used to using the treatment planning of stuff like Sidexis, which comes only with our equipment, so would I like to see this situation resolved in the first quarter, absolutely. What we’re telling you to try and be realistic is we think it’s going to flow through the year. It does move, there is movement, it’s not as if we have stopped shipping imaging products, and it’s really incumbent on us to maintain contact with that customer to reduce some of the friction that might result and then saying, hey look, I can’t wait X-number of weeks, I’m going to go to a competitor. Remember, going to that competitor involves learning a whole new software set of things, building a whole new software set of contacts with labs and other thing, so we think there’s an inherent advantage of our software and other things.

Don, the other thing that I would add is the components that we are having challenges with are not unique components or components that we own, that are very specific to our devices. Those are to a large extent generic electronic components and so the shortages are general, this is not just for us.

Understood, thanks guys.

Thank you. Next we have Matt Miksic of Credit Suisse. Your line is open.

Great, thanks very much for the questions. You’ve covered a lot here, and I won’t go back into supply chain, although I do understand it sounds like, Jorge, from your comments that if there is an unknown risk to the back half or late in the year, it sounds like that is sort of like a--you know, it’s hard to predict, so that’s sort of out there. But on pricing, love to understand if you could maybe give an update as to some of the price increases you talked about that began late last year and what--how we should think about maybe the contribution to this year, and then just one follow-up.

Yes, thank you for the question, Matt. On price, I think we are seeing good price realization relative to the October 1 price increase. It is the first phase of price increases. I think at this point, I can tell you we probably had a benefit that if you analyze it into ’22, based on this price increase we’re going to have probably a contribution of $40 million to $50 million in price increases, and then we probably will do something beyond that. It is happening, price realization is good, and there should be other opportunities in the next few quarters, few months to do more price increases in certain geographies where we haven’t rolled those out, or on certain products where we haven’t increased prices yet.

Okay, and just to be clear, you haven’t--it doesn’t sound like you’ve taken any so far this year?

Correct.

Okay, and then if I could--that’s super helpful. Then just on implants, I understand one of the bright spots in the quarter, it sounded like. Can you talk a little bit about share or opportunity to carve out share or grow through mix, maybe around some of the new product launches that you’ve talked about - Prime Taper, etc.? I know share’s hard to measure in this environment with all the ups and downs regionally, but would be super helpful to get some color if you could provide it.

Yes, thanks Matt. Look, our strategy that we’ve articulated has been okay, let’s get the business in a position to compete. We feel that we’ve got a pretty good portfolio, premium brands as well as a value brand, and then we think we have important supportive businesses if you look at our biologic and things like custom abutment. Our strategy was like, okay, let’s get competitive so that we can grow at the category rate, which we think is kind of mid to high single digits, which we think we actually gained share a little bit in the fourth quarter. As Jorge said in his prepared remarks, our expectation around implants over the course of 2022 is that we will grow at market rate. Over time, our aspiration is to take share, and again we really--we kind of do implants a little bit differently, where for us it’s about the digital work flows, so given that we just talked about Orthophos and Axeos and all that stuff, a lot of the treatment planning and software that goes into that imaging equipment and things like we did with Primescan 5.2, which gives us enhanced capabilities of looking at intraoral scanning as another diagnostic viewpoint for the dentist, we feel if we start with our digital base and we create really easy-to-use solutions and then our product’s built right in, we’d like to be able to take share. Specific bright spots, I would tell you Prime Taper we’re very excited about obviously, but MIS - you know, it’s a value business that doesn’t get as much recognition because it tends to be a little bit more of an ex-U.S. oriented brand, and when we bought the company, Datum, which is Ossix, we really felt that we got a best-in-class bone growth factor that we’re getting good traction with. Our aspiration is to gain share in our implant business, and the launch of Prime Taper as well as kind of an aggregate re-state of our implant business has a pull-through effect on the entire business, so the specific contribution of Prime Taper is not going to be in 2022 in the tens of millions, but the idea that there is a comprehensive re-stage that we’re actually offering a complete solution is very important, because implant dentists tend to pick systems and they want to know that you’re committed and they want to know that you offer the full breadth of solutions.

Great, thank you.

Thanks Matt.

We have time to take one last question, please.

Thank you. Our last question comes from Erin Wright of Morgan Stanley. Your line is open.

Great, thanks so much for squeezing me in. I had a quick question on PrimePrint and 3D printing. How would you characterize the level of demand that you anticipate across the 3D printing solutions that are out there, and how does it fit into the broader high tech equipment offering that you have and what sort of investments maybe that you need to make in and around that initiative with other ancillary products?

Yes Erin, as Jorge said, we kind of built it in the back half of our projections, but 3D printers are starting to gain traction in the marketplace. Our sense of it is there were some solutions--there’s some good competitors out there, none of them offer the level of automation, the level--easy view, some safety and some other things, we really feel that we started from what does the dentist need and go there. A lot of this, Erin, is also going to be about getting real estate. Right now, there’s some great apps that you can do on the 3D printer - night guards, surgical guides, a lot of people do 3D modeling, which is important, but ultimately where this is going to go is we think there’s going to be an opportunity as the inks get more sophisticated, that you’re going to be able to do permanent implants. I think the race is on for the ability to print that first aligner, and digital dentures is clearly something that we believe ultimately will be 3D printed, whether it’s done in the office or in the lab. In our mind, we think we’ve got a really good product that gives us a technology base that will allow us to continue to expand applications. Again, the reaction, we’ve kind of had a beta cohort for a while and they really talk about how transformative this is. In terms of investments, Eric, what we need to do, a lot of this is going to be about developing inks either internally or with partners that give you capabilities in some of the future applications around aligners and permanent implants and dentures as well, so whether those are investments or partnerships, it’s not clear right now.

Okay, great. Then you mentioned the headwinds from preventative products. Can you break out what you’re embedding in your guidance for preventative products in 2022 and how we should be thinking about that impacting broader consumables growth?

Yes Erin, I don’t think we called our preventative specifically. I mean, I think the consumable discussion was you’re up against a tough comp, as dentistry reopens and--and I think I mentioned in my prepared remarks stuff like our Palodent and other things tend to grow, but there’s parts of the portfolio as digital imaging goes up and up and up, stuff like Aquasil is going to go down, but I don’t think we called out specific prevention.

Okay, all right. Thank you.

Thank you.

Thanks Chris. Let me just close out by saying, again, we appreciate the time you spent with us. I know that we covered a lot of things. One of the discussions that we’ve had with a lot of you guys is when are we going to do an investor day. Right now, we’re targeting June because there is lots of stuff, and to be honest we’re optimistic to talk about after the restructure where are we going into the future and describe why we’re so excited about Dentsply Sirona. With that, hope everyone has a great day. Thank you.

This concludes today’s conference call. Thank you all for participating. You may now disconnect. Have a good day.